Patents by Inventor Ralf Gold
Ralf Gold has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11865091Abstract: The invention relates to an agent having immunomodulatory properties for the prevention and/or treatment of autoimmune diseases, said agent comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or C1-C8 alkyl esters, and their use as immunomodulatory agents for use in prevention and/or treatment of autoimmune related diseases and immune-mediated chronic inflammatory diseases, and dietary supplements with immunomodulating effect comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or esters comprising C1-C8 alkyl alcohols.Type: GrantFiled: June 3, 2020Date of Patent: January 9, 2024Assignee: Flexopharm Brain GMBH & Co. KGInventors: Ralf Gold, Aiden Haghikia, Ralf Linker
-
Patent number: 11471432Abstract: The invention relates to a combination therapy for the prevention and/or treatment of immune-mediated chronic inflammatory and autoimmune diseases comprising a combination of one or more C3-C8 carboxylic acids, physiologically acceptable salts and/or esters thereof, and one or more fumaric acid esters and/or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.Type: GrantFiled: June 29, 2020Date of Patent: October 18, 2022Assignee: Flexopharm Brain GMBH & Co. KGInventors: Ralf Gold, Aiden Haghikia, Ulrich Matthes
-
Publication number: 20200323802Abstract: The invention relates to a combination therapy for the prevention and/or treatment of immune-mediated chronic inflammatory and autoimmune diseases comprising a combination of one or more C3-C8 carboxylic acids, physiologically acceptable salts and/or esters thereof, and one or more fumaric acid esters and/or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.Type: ApplicationFiled: June 29, 2020Publication date: October 15, 2020Applicant: Flexopharm Brain GMBH & Co. KGInventors: RALF GOLD, Aiden Haghikia, Ulrich Matthes
-
Publication number: 20200289442Abstract: The invention relates to an agent having immunomodulatory properties for the prevention and/or treatment of autoimmune diseases, said agent comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or C1-C8 alkyl esters, and their use as immunomodulatory agents for use in prevention and/or treatment of autoimmune related diseases and immune-mediated chronic inflammatory diseases, and dietary supplements with immunomodulating effect comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or esters comprising C1-C8 alkyl alcohols.Type: ApplicationFiled: June 3, 2020Publication date: September 17, 2020Applicant: Flexopharm Brain GMBH & Co. KGInventors: RALF GOLD, Aiden Haghikia, Ralf Linker
-
Patent number: 10695305Abstract: The invention relates to a combination therapy for the prevention and/or treatment of immune-mediated chronic inflammatory and autoimmune diseases comprising a combination of one or more C3-C8 carboxylic acids, physiologically acceptable salts and/or esters thereof, and one or more fumaric acid esters and/or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.Type: GrantFiled: July 8, 2016Date of Patent: June 30, 2020Assignee: FLEXOPHARM BRAIN GMBH & CO. KGInventors: Ralf Gold, Aiden Haghikia, Ulrich Matthes
-
Patent number: 10682322Abstract: The invention relates to an agent having immunomodulatory properties for the prevention and/or treatment of autoimmune diseases, said agent comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or C1-C8 alkyl esters, and their use as immunomodulatory agents for use in prevention and/or treatment of autoimmune related diseases and immune-mediated chronic inflammatory diseases, and dietary supplements with immunomodulating effect comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or esters comprising C1-C8 alkyl alcohols.Type: GrantFiled: October 19, 2015Date of Patent: June 16, 2020Assignee: FLEXOPHARM BRAIN GMBH & GO. KGInventors: Ralf Gold, Aiden Haghikia, Ralf Linker
-
Publication number: 20180303778Abstract: The invention relates to a combination therapy for the prevention and/or treatment of immune-mediated chronic inflammatory and autoimmune diseases comprising a combination of one or more C3-C8 carboxylic acids, physiologically acceptable salts and/or esters thereof, and one or more fumaric acid esters and/or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.Type: ApplicationFiled: July 8, 2016Publication date: October 25, 2018Applicant: Flexopharm Brain GMBH & Co. KGInventors: RALF GOLD, Aiden Haghikia, Ulrich Matthes
-
Publication number: 20180271821Abstract: Methods of treating neurological disorders characterized by extensive demyelination and/or axonal loss are provided. Examples of such disorders include secondary progressive multiple sclerosis and Devic's disease. The disclosed methods include administering to a subject having such a disorder a therapeutically effective amount of, for example, dimethyl fumarate or monomethyl fumarate.Type: ApplicationFiled: May 25, 2018Publication date: September 27, 2018Applicant: Biogen MA Inc.Inventor: Ralf Gold
-
Publication number: 20180021288Abstract: Methods of treating neurological disorders, e.g., those characterized by demyelination and/or axonal loss (e.g., MS), are provided. The methods comprise administration of a therapeutically effective amount of at least one compound of Formula I: wherein R1 and R2 are independently selected from OH, O?, and (C1-6)alkoxy, or a pharmaceutically acceptable salt thereof; and either glatiramer acetate or interferon-beta.Type: ApplicationFiled: July 7, 2017Publication date: January 25, 2018Applicant: Biogen MA Inc.Inventors: Susan Goelz, Katherine Dawson, Ralf Linker, Ralf Gold
-
Publication number: 20170231933Abstract: The invention relates to an agent supporting the immunomodularity for the treatment of autoimmune diseases, said agent containing C3-C8 carboxylic acids, their physiologically tolerable salts and/or esters with C1-C8 alkyl alcohols, their use as supporting immunomodulators for autoimmune related diseases and immune-mediated chronic inflammatory diseases, as well as dietary supplements with immunomodulating effect containing these.Type: ApplicationFiled: October 19, 2015Publication date: August 17, 2017Applicant: Flexopharm Brain GMBH & Co. KGInventors: RALF GOLD, Aiden Haghikia, Ralf Linker
-
Publication number: 20160250172Abstract: Methods of treating neurological disorders, e.g., those characterized by demyelination and/or axonal loss (e.g., MS), are provided. The methods comprise administration of a therapeutically effective amount of at least one compound of Formula I: wherein R1 and R2 are independently selected from OH, O?, and (C1-6)alkoxy, or a pharmaceutically acceptable salt thereof; and either glatiramer acetate or interferon-beta.Type: ApplicationFiled: March 1, 2016Publication date: September 1, 2016Inventors: Susan Goelz, Katherine Dawson, Ralf Linker, Ralf Gold
-
Publication number: 20150267254Abstract: The invention provides a method of determining if a patient is afflicted with multiple sclerosis (MS) using microRNA (miRNA) profiles of specific miRNAs that are present in the cerebrospinal fluid (CSF). This method can also be used to discriminate different forms of MS. The invention further comprises a kit for diagnosing or monitoring MS based upon the miRNA profiles according to the invention, and also relates to the use of said miRNA profiles in the diagnosis or monitoring of MS.Type: ApplicationFiled: July 5, 2013Publication date: September 24, 2015Applicants: MEDIZINISCHE HOCHSHULE HANNOVER, ST. JOSEF - UND ST. ELISABETH HOSPITAL GMBHInventors: Thomas Thum, Aiden Haghikia, Arash Haghikia, Ralf Gold
-
Publication number: 20140323570Abstract: Methods of treating neurological disorders characterized by extensive demyelination and/or axonal loss are provided. Examples of such disorders include secondary progressive multiple sclerosis and Devic's disease. The disclosed methods include administering to a subject having such a disorder a therapeutically effective amount of, for example, dimethyl fumarate or monomethyl fumarate.Type: ApplicationFiled: April 29, 2014Publication date: October 30, 2014Applicant: Biogen Idec MA Inc.Inventor: Ralf GOLD
-
Publication number: 20130302410Abstract: Methods of treating neurological disorders characterized by extensive demyelination and/or axonal loss are provided. Examples of such disorders include secondary progressive multiple sclerosis and Devic's disease. The disclosed methods include administering to a subject having such a disorder a therapeutically effective amount of, for example, dimethyl fumarate or monomethyl fumarate.Type: ApplicationFiled: March 14, 2013Publication date: November 14, 2013Inventor: Ralf GOLD
-
Publication number: 20130287732Abstract: Methods of treating neurological disorders, e.g., those characterized by demyelination and/or axonal loss (e.g., MS), are provided. The methods comprise administration of a therapeutically effective amount of at least one compound of Formula I: wherein R1 and R2 are independently selected from OH, O?, and (C1-6)alkoxy, or a pharmaceutically acceptable salt thereof; and either glatiramer acetate or interferon-beta.Type: ApplicationFiled: March 25, 2013Publication date: October 31, 2013Inventors: Susan GOELZ, Katherine Dawson, Ralf Linker, Ralf Gold
-
Publication number: 20100130607Abstract: Methods of treating neurological disorders characterized by extensive demyelination and/or axonal loss are provided. Examples of such disorders include secondary progressive multiple sclerosis and Devic's disease. The disclosed methods include administering to a subject having such a disorder a therapeutically effective amount of, for example, dimethyl fumarate or monomethyl fumarate.Type: ApplicationFiled: February 7, 2008Publication date: May 27, 2010Inventor: Ralf Gold
-
Patent number: 6319892Abstract: The present invention relates to the use of recombinant myelin protein for treating T cell-mediated autoimmune diseases of the peripheral nervous system.Type: GrantFiled: March 15, 1999Date of Patent: November 20, 2001Inventors: Ralf Gold, Andreas Weishaupt